PPI INDUCED RENAL TOXICITY

被引:0
作者
Sara, K. [1 ]
机构
[1] Vishwa Bharathi Coll Pharmaceut Sci, Dept Pharm Practice, Guntur 09, Andhra Pradesh, India
来源
INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES | 2019年 / 6卷 / 02期
关键词
Glomerular filtration; hyperplasia; hypertrophy; hypergastrinemia; hyperchlorhydria; PROTON PUMP INHIBITOR; OMEPRAZOLE; PANTOPRAZOLE; MECHANISM; RISK;
D O I
10.5281/zenodo.2574961
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
PPIs are mostly used drugs in many prescriptions along with drugs for other co-morbidities and also used for long time periods and as OTC drugs (medication). These drugs on prolong use causes renal toxicity in many cases by affecting glomerular filtration and also through several cases like increase in pH, gastroenteritis, hyperplasia, hypertrophy, hypergastrinemia, hyperchlorhydria, and effect on mitochondrial cells. The unrequited actions by PPIs also can appear in paediatrics along with adults. In this paper we will review about brief information regarding pharmacokinetics and pharmacodynamics of proton pump inhibitors and those several adverse pathways, physiologies and the alternative to prevent these conditions.
引用
收藏
页数:6
相关论文
共 29 条
[1]  
Alper Brent, 2017, MEDSCAPE
[2]   MEMBRANE TOPOLOGY AND OMEPRAZOLE LABELING OF THE GASTRIC H+,K+-ADENOSINE-TRIPHOSPHATASE [J].
BESANCON, M ;
SHIN, JM ;
MERCIER, F ;
MUNSON, K ;
MILLER, M ;
HERSEY, S ;
SACHS, G .
BIOCHEMISTRY, 1993, 32 (09) :2345-2355
[3]   A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use [J].
Blank, Mei-Ling ;
Parkin, Lianne ;
Paul, Charlotte ;
Herbison, Peter .
KIDNEY INTERNATIONAL, 2014, 86 (04) :837-844
[4]  
Boron Walter F., MED PHYSL CELLULAR M, P743
[5]  
Dean L., 2010, PUBMED CLIN Q A
[6]  
Fillastre JP, ANN BIOL CLIN
[7]   EFFECTS OF THE PROTON PUMP INHIBITOR, E3810, ON GASTRIC-SECRETION AND GASTRIC AND DUODENAL-ULCERS OR EROSIONS IN RATS [J].
FUJISAKI, H ;
SHIBATA, H ;
OKETANI, K ;
MURAKAMI, M ;
FUJIMOTO, M ;
WAKABAYASHI, T ;
YAMATSU, I ;
TAKEGUCHI, N .
DRUG INVESTIGATION, 1991, 3 (05) :328-332
[8]  
Gerard J. Tortora, 2010, PRINCIPLES ANATOMY P, P1024
[9]  
Gerard J. Tortora, 2010, PRINCIPLES ANATOMY P, P1027
[10]  
Hagymási K, 2011, PHARMACOGENOMICS, V12, P873, DOI [10.2217/pgs.11.4, 10.2217/PGS.11.4]